Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 7, 2006, Pages 345-351

  Chung, Hye J ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

Ipriflavone; Pharmacokinetics; Rats; U ARF

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C11; GLUCURONIDE; IPRIFLAVONE; MESSENGER RNA; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; KIDNEY CLEARANCE; LIVER MICROSOME; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; INJECTIONS, INTRAVENOUS; ISOFLAVONES; KIDNEY FAILURE; MALE; RATS; RATS, SPRAGUE-DAWLEY; URANYL NITRATE;

EID: 33750622003     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.515     Document Type: Article

References (27)

1. Takenaka M, Nakata M, Tsubioi S, Fujita T. Vitamin D. Biochemical and Clinical Endocrinology of Calcium Metabolism. Walter de Guyter: Berlin, New York, 1982.
2. Kakai Y, Kawase T, Nakano T, Mikuni-Takagaki Y, Saito S. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 1992; 51(Suppl. 1): S11-S15.
3. Reginster J-YL. Ipriflavone: Pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993; 23: 223-232.
4. Katase K, Kato T, Hirai Y, Hasumi K, Chem JT. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: A randomized placebo controlled study. Calcif Tissue Int 2001; 69: 73-77.
5. Deyhim F, Smith BJ, Soung DY, Juma S, Devareddy L, Arjmandi BH. Ipriflavone modulates IGF-I but is unable to restore bone in rats. Phytother Res 2005; 19: 116-120.
6. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1-S34.
7. Chung HJ, Choi YH, Kim SH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol 2006; 58: 449-457.
8. Chung HC, Kim SH, Lee MG, Kim SG. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by acute renal failure. Drug Metab Dispos 2002; 30: 739-746.
9. Moon YJ, Lee AK, Chung HC, et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
10. Weisinger JR, Bellorine-Font E. Postmenopausal osteoporosis in the dialysis patient. Curr Opin Nephrol Hypertens 2003; 12: 381-386.
11. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093.
12. Talbert RL. Drug dosing in renal insufficiency. J Clin Pharmacol 1994; 34: 99-110.
13. Kim SH, Lee MG. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. Life Sci 2002; 70: 1299-1315.
14. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
15. Kim SH, Lee JS, Lee MG. Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits. Biopharm Drug Dispos 2000; 21: 147-156.
16. Kim SH, Lee JS, Lee MG. Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 1997; 98: 313-324.
17. Kim SH, Lee JS, Lee MG. Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative. Biopharm Drug Dispos 1999; 20: 355-360.
18. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
19. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel-Dekker: New York, 1982.
20. Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
21. Eatman PB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
22. Chiou WL. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 1980; 69: 90-91.
23. Yu SY, Chung HC, Kim EJ, et al. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. J Pharm Pharmacol 2002; 54: 1687-1692.
24. Lee EJ, Kim EJ, Kim YG, et al. Pharmacokinetic changes of intravenous 2-(allylthio)pyrazine, a chemoprotective agent, in rats with acute renal failure induced by uranyl nitrate. Res Commun Mol Pathol Pharmacol 2002; 111: 225-234.
25. Rohatagi C, Barrett JS, Sawyers W, Yu K, Morales RJ. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the osteofix tablet. Am J Ther 1997; 4: 229-238.
26. Rondelli I, Acerbi D, Ventura P. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. Int J Clin Pharmacol Res 1991; 11: 183-192.
27. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug-metabolism by the liver. Br J Anaesth 1993; 71: 282-290.